February 1, 2023Recently, Beijing Beilu Pharmaceutical Co., Ltd. was once again awarded the title of "Class A Unit for Safety Production" in Miyun Park of Zhongguancun District. The company has won this awa...view
March 22, 2024Recently, Beilu Pharmaceutical received the "Drug Supplementary Application Approval Notice" (Notice Number: 2024B01144) for Gadobenate Dimeglumine Injection issued by the National Medical P...view
December 17, 2024On December 12, 2024, Beilu Pharmaceutical participated in the bidding process for the 10th National Drug Centralized Procurement organized by the National Joint Drug Procurement Office. Beilu Pharmac...view
December 2, 2021To further promote the development of the company's main business and enhance the company's competitiveness, Zhejiang Hichi Pharmaceutical Co., Ltd., its holding subsidiary, launched a new ...view
December 20, 2021Now, our company received the Notification of Approval of Supplementary Application for Repaglinide Tablets issued by the State Medical Products Administration (Notification No. : 2021 B04618). After ...view
July 5, 2022Ⅰ. What is the contrast material?Contrastive material is used to improve the contrast of the images produced by X-rays, computed tomography (CT), magnetic resonance (MR) imaging, and ultrasound, allo...view